Related references
Note: Only part of the references are listed.Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six-arm placebo-controlled trial in healthy women
Marike Gabrielson et al.
INTERNATIONAL JOURNAL OF CANCER (2023)
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study
Matteo Lazzeroni et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer
Smita Bhatia et al.
CLINICAL CANCER RESEARCH (2021)
Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer
Andras Inotai et al.
CANCER TREATMENT REVIEWS (2021)
The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis
Nicola Peddie et al.
BREAST (2021)
Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial
Mikael Eriksson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Hormonal determinants of mammographic density and density change
Marike Gabrielson et al.
BREAST CANCER RESEARCH (2020)
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia
Andrea DeCensi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Medication Use for the Risk Reduction of Primary Breast Cancer in Women Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
Heidi D. Nelson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Medication Use to Reduce Risk of Breast Cancer US Preventive Services Task Force Recommendation Statement
Douglas K. Owens et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Association of reproductive history with breast tissue characteristics and receptor status in the normal breast
Marike Gabrielson et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)
Samuel George Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?
Katherine D. Crew et al.
NPJ BREAST CANCER (2017)
Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis
S. G. Smith et al.
ANNALS OF ONCOLOGY (2016)
Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1
Stephanie R. Land et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1
Stephanie R. Land et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer
Wei He et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature review
Peter Andrew et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Validity and Reliability of the Swedish Version of the Memorial Symptom Assessment Scale (MSAS): An Instrument for the Evaluation of Symptom Prevalence, Characteristics, and Distress
Maria Browall et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2013)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
Agreement of Mammographic Measures of Volumetric Breast Density to MRI
Jeff Wang et al.
PLOS ONE (2013)
Body composition changes in females treated for breast cancer: a review of the evidence
Patricia M. Sheean et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010
Erika A. Waters et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Predicting Adherence to Tamoxifen for Breast Cancer Adjuvant Therapy and Prevention
Jennifer H. Lin et al.
CANCER PREVENTION RESEARCH (2011)
Patient Decisions About Breast Cancer Chemoprevention: A Systematic Review and Meta-Analysis
Mary E. Ropka et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer
C. McCowan et al.
BRITISH JOURNAL OF CANCER (2008)
Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy
David Cella et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Adherence to tamoxifen over the five-year course
Timothy L. Lash et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
Stephanie R. Land et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
Victor G. Vogel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer - Results from International Breast Cancer Study Group Trials
L Gianni et al.
CANCER (2006)
The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators
RM O'Regan et al.
LANCET ONCOLOGY (2002)
Drug therapy - Side effects of adjuvant treatment of breast cancer
CL Shapiro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Tamoxifen for the prevention of breast cancer: Psychosocial impact on women participating in two randomized controlled trials
L Fallowfield et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
